Activin A circulating levels in patients with bone metastasis from breast or prostate cancer

Clinical and Experimental Metastasis

Volumn 23, Issue 2, 2006, Pages 117-122

  Leto, Gaetano ^a   Incorvaia, Lorena ^a   Badalamenti, Giuseppe ^a   Tumminello, Francesca M ^a   Gebbia, Nicola ^a   Flandina, Carla ^a   Crescimanno, Marilena ^a   Rini, Giovambattista ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Activin A; Benign prostatic hypertrophy; Bone metastasis; Breast cancer; Neoplasm; Osteoporosis; Prostate cancer; Transforming growth factor ; Tumor markers

Indexed keywords

ACTIVIN A; BIOCHEMICAL MARKER; CYTOKINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD DONOR; BONE METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; RECEIVER OPERATING CHARACTERISTIC;

ACTIVINS; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33748954261     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-006-9010-5     Document Type: Article

References (34)

1. Luisi S, Florio P, Reis FM, Petraglia F (2001) Expression and secretion of Activin A: possible physiological and clinical implications. Eur J Endocrinol 145:225-236
2. Tsuchida K (2004) Activins, myostatin and related TGF-β family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 4:157-166
3. Risbridger GP, Schmitt JF, Robertson DM (2001) Activins and inhibins in endocrine and other tumors. Endocr Rev 22(6):836-858
4. Chen Y-G, Lui HM, Lin S-H et al (2002) Regulation of cell proliferation, apoptosis and carcinogenesis by activin. Exp Biol Med 227(2):75-88
5. Werner S, Alzheimer C (2006) Roles of activin in tissue repair, fibrosis and inflammatory disease. Cytokine Growth Factor Rev (in press) DOI: 10.1016/j.cytogfr.2006.01.001
6. Fuller K, Bayley KE, Chambers TJ (2000) Activin A is an essential cofactor for osteoclast induction. Biochem Biophys Res Comm 268:2-7
7. Sugatani T, Alvarez UM, Hruska KA (2003) Activin A stimulates IkB-a/NFkB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem 90:59-67
8. Sakai R, Yuzuru E (2001) Involvement of activin in the regulation of bone metabolism. Mol Cell Endocrinol 180:183-188
9. Harrison GA, Gray PC, Vale WW et al (2005) Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 16(2):73-78
10. Reinholz M, Iturria SJ, Ingle JN, Roche PC (2002) Differential gene expression of TGF-β family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR. Breast Cancer Res Treat 74:255-269
11. Reis F, Cobellis L, Tameirão LC et al (2002) Serum and tissue expression of activin A in postmenopausal women with breast cancer. J Clin Endocrinol Metab 87(5):2277-2282
12. Dowling CR, Risbridger GP (2004) The role of inhibins and activins in prostate cancer pathogenesis. Endocr Relat Cancer 7:243-256
13. Robertson DM, Burger HG, Fuller PJ (2004) Inhibin/activin and ovarian cancer. Endocr Relat Cancer 11:35-49
14. Wildi S, Kleeff J, Maruyama H et al (2001) Overexpression of activin A in stage IV colorectal cancer. Gut 49:409-417
15. Yuen MF, Norris S, Evans LW et al (2002) Transforming growth factor-beta 1, activin and follistatin in patients with hepatocellular carcinoma and patients with alcoholic cirrhosis. Scand J Gastroenterol 37(2):233-238
16. Pirisi M, Fabris C, Luisi S et al (2000) Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma. Cancer Detect Prev 24(2):150-155
17. Kleeff J, Ishiwata T, Friess H et al (1998) Concomitant overexpression of activin/inhibin b subunits and their receptors in human pancreatic cancer. Int J Cancer 77:860-868
18. Schulte KM, Jonas C, Krebs R, Roher HD (2001) Activin A and activin receptors in thyroid cancer. Thyroid 11(1):3-14
19. Yoshinaga K, Mimori K, Yamashita K et al (2003) Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol 22(1):75-80
20. Schramm A, von Schuetz V, Christiansen H et al (2005) High activin A expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome. Oncogene. 24(4):680-687
21. Matsuyama S, Iwadate M, Kondo M et al (2003) SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer Res 63(22):7791-7798
22. Sakai R, Eto Y, Hirafuji M, Shinoda H (2000) Activin release from bone coupled to bone resorption in organ culture of neonatal mouse calvaria. Bone 26:235-240
23. Roodman GD (2004) Mechanism of bone metastasis. N Eng J Med 350:1655-1664
24. World Medical Association Declaration of Helsinki (1997) Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925-926
25. Lambert-Messerlian GM, DePasquale SE, Maybruck WM et al (1999) Secretion of Activin A in recurrent epithelial ovarian carcinoma. Gynecol Oncol 74:93-97
26. Chang H, Brown CW, Matzuk MM (2002) Genetic analysis of the mammalian transforming growth factor-β- superfamily. Endocr Rev 23:787-823
27. Rossi MR, Ionov Y, Bakin AV, Cowell JK (2005) Truncating mutations in the ACVR2 gene attenuates activin signalling in prostate cancer cells. Cancer Genet Cytogenet 163:123-129
28. Jeruss JS, Sturgis CD, Rademaker AW, Woodruff TK (2003) Down-regulation of activin, activin receptors and Smads in high grade breast cancer. Cancer Res 63:783-790
29. Carey JL, Sasur LM, Kawakubo H et al (2004) Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth. Mol Endocrinol 18:696-707
30. Hyuga S, Kawasaki N, Hashimoto O et al (2000) Possible role of hepatocyte growth factor/scatter factor and activin A produced by the target organ in liver metastasis. Cancer Lett 153:137-143
31. Koeneman K, Yeung F, Chung WK (1999) Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate 39:246-261
32. Keller E, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718-729
33. Fujii Y, Kawakami S, Okada Y et al (2004) Regulation of prostate-specific antigen by Activin A in prostate cancer LNCaP cells. Am J Physiol Endocrinol Metab 286(6):E927-E931
34. Cardillo MR, Petrangeli E, Perracchio L et al (2000) Transforming growth factor-beta expression in prostate neoplasia. Anal Quant Cytol Histol 22(1):1-10